1
|
Mallart S, Ingenito R, Bianchi E, Bresciani A, Esposito S, Gallo M, Magotti P, Monteagudo E, Orsatti L, Roversi D, Santoprete A, Tucci F, Veneziano M, Bartsch R, Boehm C, Brasseur D, Bruneau P, Corbier A, Froissant J, Gauzy-Lazo L, Gervat V, Marguet F, Menguy I, Minoletti C, Nicolas MF, Pasquier O, Poirier B, Raux A, Riva L, Janiak P, Strobel H, Duclos O, Illiano S. Identification of Potent and Long-Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases. J Med Chem 2021; 64:2139-2150. [PMID: 33555858 DOI: 10.1021/acs.jmedchem.0c01533] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The insulin-like peptide human relaxin-2 was identified as a hormone that, among other biological functions, mediates the hemodynamic changes occurring during pregnancy. Recombinant relaxin-2 (serelaxin) has shown beneficial effects in acute heart failure, but its full therapeutic potential has been hampered by its short half-life and the need for intravenous administration limiting its use to intensive care units. In this study, we report the development of long-acting potent single-chain relaxin peptide mimetics. Modifications in the B-chain of relaxin, such as the introduction of specific mutations and the trimming of the sequence to an optimal size, resulted in potent, structurally simplified peptide agonists of the relaxin receptor Relaxin Family Peptide Receptor 1 (RXFP1) (e.g., 54). Introduction of suitable spacers and fatty acids led to the identification of single-chain lipidated peptide agonists of RXFP1, with sub-nanomolar activity, high subcutaneous bioavailability, extended half-lives, and in vivo efficacy (e.g., 64).
Collapse
Affiliation(s)
- Sergio Mallart
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Raffaele Ingenito
- Peptides and Small Molecules R&D Department, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Elisabetta Bianchi
- Peptides and Small Molecules R&D Department, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Alberto Bresciani
- Department of Translational Biology, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Simone Esposito
- DMPK, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Mariana Gallo
- Structural Biology, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Paola Magotti
- Peptides and Small Molecules R&D Department, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Edith Monteagudo
- DMPK, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Laura Orsatti
- DMPK, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Daniela Roversi
- Peptides and Small Molecules R&D Department, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Alessia Santoprete
- Peptides and Small Molecules R&D Department, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Federica Tucci
- Peptides and Small Molecules R&D Department, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Maria Veneziano
- DMPK, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Régine Bartsch
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Claudius Boehm
- Industrial Affairs, iCMC, Sanofi-Aventis R&D, Industriepark Höchst, Frankfurt 65926, Germany
| | - Denis Brasseur
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Patricia Bruneau
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Alain Corbier
- Cardio-Vascular and metabolism, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Jacques Froissant
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Laurence Gauzy-Lazo
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Vincent Gervat
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Frank Marguet
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Isabelle Menguy
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Claire Minoletti
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Marie-Françoise Nicolas
- Preclinical Development Sciences, Sanofi R&D, 13 quai Jules Guesde, Vitry sur Seine 94400, France
| | - Olivier Pasquier
- DMPK France, Sanofi R&D, 3 digue d'Alfortville, Alfortville 94140, France
| | - Bruno Poirier
- Cardio-Vascular and metabolism, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Alexandre Raux
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Laurence Riva
- Cardio-Vascular and metabolism, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Philip Janiak
- Cardio-Vascular and metabolism, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Hartmut Strobel
- Peptides and Small Molecules R&D Department, IRBM Spa, Via Pontina Km 30 600, Pomezia, Rome 00 071, Italy
| | - Olivier Duclos
- Integrated Drug Discovery, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| | - Stephane Illiano
- Cardio-Vascular and metabolism, Sanofi R&D, 1 rue Pierre Brossolette, Chilly Mazarin 91385, France
| |
Collapse
|
2
|
Koundinya M, Sudhalter J, Courjaud A, Lionne B, Touyer G, Bonnet L, Menguy I, Schreiber I, Perrault C, Vougier S, Benhamou B, Zhang B, He T, Gao Q, Gee P, Simard D, Castaldi MP, Tomlinson R, Reiling S, Barrague M, Newcombe R, Cao H, Wang Y, Sun F, Murtie J, Munson M, Yang E, Harper D, Bouaboula M, Pollard J, Grepin C, Garcia-Echeverria C, Cheng H, Adrian F, Winter C, Licht S, Cornella-Taracido I, Arrebola R, Morris A. Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers. Cell Chem Biol 2018; 25:705-717.e11. [PMID: 29628435 DOI: 10.1016/j.chembiol.2018.03.005] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Revised: 12/29/2017] [Accepted: 03/08/2018] [Indexed: 12/13/2022]
Abstract
Activating KRAS mutations are major oncogenic drivers in multiple tumor types. Synthetic lethal screens have previously been used to identify targets critical for the survival of KRAS mutant cells, but their application to drug discovery has proven challenging, possibly due in part to a failure of monolayer cultures to model tumor biology. Here, we report the results of a high-throughput synthetic lethal screen for small molecules that selectively inhibit the growth of KRAS mutant cell lines in soft agar. Chemoproteomic profiling identifies the target of the most KRAS-selective chemical series as dihydroorotate dehydrogenase (DHODH). DHODH inhibition is shown to perturb multiple metabolic pathways. In vivo preclinical studies demonstrate strong antitumor activity upon DHODH inhibition in a pancreatic tumor xenograft model.
Collapse
Affiliation(s)
| | - Judith Sudhalter
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | | | | | | | - Luc Bonnet
- LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France
| | | | | | | | | | | | - Bailin Zhang
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Timothy He
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Qiang Gao
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Patricia Gee
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Daniel Simard
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA; Chemistry, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | | | | | - Stephan Reiling
- LGCR-SDI, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | | | - Richard Newcombe
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Hui Cao
- TEM-BioInformatics, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Yanjun Wang
- In Vivo Pharmacology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Fangxian Sun
- In Vivo Pharmacology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Joshua Murtie
- In Vivo Pharmacology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Mark Munson
- LGCR, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Eric Yang
- TEM-BioInformatics, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - David Harper
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Monsif Bouaboula
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Jack Pollard
- TEM-BioInformatics, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | | | - Carlos Garcia-Echeverria
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Hong Cheng
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Francisco Adrian
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | | | - Stuart Licht
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
| | | | | | - Aaron Morris
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
| |
Collapse
|
3
|
Koundinya M, Sudhalter J, Courjaud A, Lionne B, Touyer G, Bonnet L, Menguy I, Schreiber I, Perrault C, Vougier S, Benhamou B, Simard D, Castaldi MP, Tomlinson R, Reiling S, Cao H, Harper D, Bouaboula M, Pollard J, Grepin C, Garcia-Echeverria C, Adrian F, Cornella-Taracido I, Arrebola R, Morris AJ. Abstract 2243: Clonogenic 3D high throughput screening in mutant KRAS dependent cancer cells - a chemogenomic approach. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-2243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Activating KRAS mutations are oncogenic and prevalent in multiple tumor types, being found in as high as 90% of pancreatic carcinomas and 50% of colorectal carcinomas. In spite of its attractiveness for therapeutic intervention to date no KRAS-targeted drug therapies have been approved. Most of the reported mutant KRAS directed cellular screening efforts utilize 2-dimensional assays. Because mutant KRAS driven tumor cell lines are much more strongly dependent on activated K-Ras signaling for anchorage independent growth relative to growth when anchored to plastic, we report herein a screening strategy that leverages a 3-dimensional clonogenic growth assay in soft agar. We have performed a multi-cell line parallel phenotypic high throughput screen with our proprietary compound collection to identify pathways, targets and chemical matter with selective anti-tumor activity in mutant KRAS dependent cell lines - a Synthetic Lethal approach.
Our strategy has led to the identification of several chemical classes that inhibit the growth of multiple mutant KRAS cell lines of pancreatic and colorectal carcinoma origin, while sparing multiple wild-type KRAS cancer cell lines. Studies to elucidate their molecular mechanisms of action are underway.
Citation Format: Malvika Koundinya, Judith Sudhalter, Albane Courjaud, Bruno Lionne, Gaetan Touyer, Luc Bonnet, Isabelle Menguy, Isabelle Schreiber, Christelle Perrault, Stephanie Vougier, Brigitte Benhamou, Daniel Simard, Maria Paola Castaldi, Ronald Tomlinson, Stephan Reiling, Hui Cao, David Harper, Monsif Bouaboula, Jack Pollard, Claudine Grepin, Carlos Garcia-Echeverria, Francisco Adrian, Ivan Cornella-Taracido, Rosalia Arrebola, Aaron J. Morris. Clonogenic 3D high throughput screening in mutant KRAS dependent cancer cells - a chemogenomic approach. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2243. doi:10.1158/1538-7445.AM2013-2243
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Hui Cao
- 1Sanofi Oncology, Cambridge, MA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Roux P, Menguy I, Soubigou S, Chinn J, Ricard S, Williams S, Guitton JD, Tian T, Singh S, Grépin C. Direct measurement of multiple mRNAs in nerve growth factor-induced PC12 cells using electrophoretic tags to monitor biomarkers of neuronal differentiation in 96-well format. Assay Drug Dev Technol 2005; 2:637-46. [PMID: 15674022 DOI: 10.1089/adt.2004.2.637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
Pheochromocytoma-12 (PC12) cells recapitulate the program of neuronal differentiation by developing neurites after about 12 days of nerve growth factor (NGF) treatment. This model can be used to evaluate the neuroprotective/neurotrophic effect of compounds. Specific mRNAs such as cfos and c-jun are early biomarkers of the irreversible commitment into the differentiation program as they appear after only 30-40 min of NGF treatment. Monitoring the level of these mRNAs instead of the neurite outgrowth dramatically reduces the time needed to identify the drug potential of compounds. The electrophoretic tags, or eTag reporters (ACLARA Biosciences, Inc., Mountain View, CA), are a new class of fluorescent reporters that have unique migration properties in capillary electrophoresis, which allows for their separation and identification. (The eTag Multiplex Invader Assay and products incorporate Invader technology and Cleavase enzyme licensed for use from Third Wave Technologies, Inc. [Madison, WI] for multiplexed gene expression applications.) Each eTag molecule used begins as a phosphoramidite that is incorporated into a specific oligonucleotide using standard oligonucleotide synthesis procedures. A set of distinct probes labeled with different eTag molecules can then be mixed together to simultaneously quantify the levels of different mRNAs from the same sample. When compared to existing methods for measuring multiplexed gene expression from the same sample, the eTag assay allows a direct quantification of the mRNA from cells without any extraction/purification and still provides multiplexing capability, high sensitivity, miniaturization, and reproducibility compatible with medium-throughput screening methods. The eTag technology was used to simultaneously measure the level of expression of four mRNAs-c-fos, c-jun, c-myc, and gapdh-in NGF-treated PC12 cells in a standard 96-well format. The experimental data shown here demonstrate the use of eTag technology as a new screening tool, which uniquely combines robustness, sensitivity, multiplexing capability, and direct measurement of mRNA without any sample preparation steps, such as RNA extraction/purification or a reverse transcription step.
Collapse
|